11,200 Shares in The Cooper Companies, Inc. (NASDAQ:COO) Acquired by Andra AP fonden

Andra AP fonden bought a new stake in The Cooper Companies, Inc. (NASDAQ:COO) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 11,200 shares of the medical device company’s stock, valued at approximately $1,030,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Fulton Bank N.A. grew its stake in shares of Cooper Companies by 3.0% in the 4th quarter. Fulton Bank N.A. now owns 3,718 shares of the medical device company’s stock valued at $342,000 after purchasing an additional 109 shares during the last quarter. Torray Investment Partners LLC grew its stake in shares of Cooper Companies by 0.8% in the 4th quarter. Torray Investment Partners LLC now owns 16,190 shares of the medical device company’s stock valued at $1,488,000 after purchasing an additional 132 shares during the last quarter. Mather Group LLC. grew its stake in shares of Cooper Companies by 7.4% in the 4th quarter. Mather Group LLC. now owns 1,926 shares of the medical device company’s stock valued at $177,000 after purchasing an additional 133 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its stake in shares of Cooper Companies by 15.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,008 shares of the medical device company’s stock valued at $93,000 after purchasing an additional 136 shares during the last quarter. Finally, Greenleaf Trust grew its stake in shares of Cooper Companies by 5.0% in the 4th quarter. Greenleaf Trust now owns 2,915 shares of the medical device company’s stock valued at $268,000 after purchasing an additional 139 shares during the last quarter. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. StockNews.com downgraded Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Citigroup decreased their price target on Cooper Companies from $115.00 to $110.00 and set a “buy” rating on the stock in a research note on Friday. Morgan Stanley decreased their price target on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research note on Friday, December 6th. Stifel Nicolaus decreased their price target on Cooper Companies from $115.00 to $105.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a research note on Friday. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $111.89.

Cooper Companies Stock Performance

Shares of COO stock opened at $85.00 on Monday. The stock has a fifty day moving average price of $92.38 and a 200 day moving average price of $99.44. The stock has a market cap of $16.96 billion, a PE ratio of 43.59, a P/E/G ratio of 2.25 and a beta of 1.02. The Cooper Companies, Inc. has a 1 year low of $82.61 and a 1 year high of $112.38. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The firm had revenue of $964.70 million during the quarter, compared to analysts’ expectations of $981.25 million. Sell-side analysts forecast that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.